Q1 2018 EPS Estimates for Impax Laboratories Inc Cut by Leerink Swann (IPXL)

Impax Laboratories Inc (NASDAQ:IPXL) – Investment analysts at Leerink Swann reduced their Q1 2018 EPS estimates for shares of Impax Laboratories in a research report issued to clients and investors on Monday, April 16th. Leerink Swann analyst A. Fadia now forecasts that the specialty pharmaceutical company will earn $0.15 per share for the quarter, down from their prior forecast of $0.17. Leerink Swann currently has a “Outperform” rating and a $22.00 target price on the stock. Leerink Swann also issued estimates for Impax Laboratories’ Q2 2018 earnings at $0.35 EPS and Q4 2018 earnings at $0.42 EPS.

How to Become a New Pot Stock Millionaire

Impax Laboratories (NASDAQ:IPXL) last issued its quarterly earnings results on Thursday, March 1st. The specialty pharmaceutical company reported $0.11 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.12 by ($0.01). The company had revenue of $182.90 million during the quarter, compared to analysts’ expectations of $199.13 million. Impax Laboratories had a positive return on equity of 10.42% and a negative net margin of 60.49%. The company’s revenue for the quarter was down 7.8% compared to the same quarter last year. During the same period in the prior year, the business posted $0.16 EPS.

IPXL has been the topic of several other research reports. Canaccord Genuity set a $19.00 target price on Impax Laboratories and gave the company a “hold” rating in a research note on Monday, December 18th. BMO Capital Markets lifted their target price on Impax Laboratories from $18.00 to $20.00 and gave the company a “market perform” rating in a research note on Monday. Zacks Investment Research raised Impax Laboratories from a “hold” rating to a “buy” rating and set a $23.00 target price on the stock in a research note on Friday, March 16th. Cantor Fitzgerald set a $35.00 target price on Impax Laboratories and gave the company a “buy” rating in a research note on Thursday, March 1st. Finally, BidaskClub cut Impax Laboratories from a “hold” rating to a “sell” rating in a research note on Friday, February 16th. Five research analysts have rated the stock with a sell rating, eight have given a hold rating and six have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $21.15.

Shares of IPXL opened at $19.00 on Tuesday. The stock has a market capitalization of $1,355.54, a P/E ratio of 29.13, a P/E/G ratio of 0.82 and a beta of 1.17. Impax Laboratories has a 1-year low of $12.45 and a 1-year high of $25.70. The company has a debt-to-equity ratio of 4.11, a quick ratio of 1.52 and a current ratio of 1.96.

Institutional investors have recently made changes to their positions in the company. Xact Kapitalforvaltning AB acquired a new stake in shares of Impax Laboratories during the 4th quarter valued at about $198,000. BlueCrest Capital Management Ltd acquired a new stake in shares of Impax Laboratories during the 4th quarter valued at about $336,000. Envestnet Asset Management Inc. lifted its holdings in shares of Impax Laboratories by 470.9% during the 4th quarter. Envestnet Asset Management Inc. now owns 20,581 shares of the specialty pharmaceutical company’s stock valued at $343,000 after buying an additional 16,976 shares during the last quarter. Teacher Retirement System of Texas acquired a new stake in shares of Impax Laboratories during the 4th quarter valued at about $393,000. Finally, Commerce Bank lifted its holdings in shares of Impax Laboratories by 112.7% during the 4th quarter. Commerce Bank now owns 24,375 shares of the specialty pharmaceutical company’s stock valued at $406,000 after buying an additional 12,915 shares during the last quarter. Institutional investors and hedge funds own 90.40% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this report on another website, it was illegally copied and reposted in violation of United States & international copyright and trademark law. The legal version of this report can be read at https://www.chaffeybreeze.com/2018/04/17/q1-2018-eps-estimates-for-impax-laboratories-inc-cut-by-leerink-swann-ipxl.html.

Impax Laboratories Company Profile

Impax Laboratories, Inc is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma.

Earnings History and Estimates for Impax Laboratories (NASDAQ:IPXL)

Receive News & Ratings for Impax Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Impax Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply